Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial중증 코로나19 폐렴으로 입원한 환자를 대상으로 한 토실리주맙과 렘데시비르: 무작위 임상시험Randomized Controlled Trial Published on 2021-11-012022-09-11 Journal: Intensive care medicine [Category] 임상, 진단, 치료제, [키워드] 7-category ordinal scale 95% CI adverse event assigned benefit clinical status Combination Corticosteroid Corticosteroids COVID-19 COVID-19 pneumonia Cox proportional hazard defined demonstrated died double-blind enrolled evaluated greater hospital discharge hospitalized patient intravenously investigator median time Multicenter trial occurred Ordinal Scale other treatment other treatments oxygen Patient patients patients hospitalized Placebo placebo-controlled Pneumonia Primary outcome provide randomization Randomized randomized clinical trial Randomly receive Remdesivir Serious Adverse Events severe COVID-19 Severe COVID-19 pneumonia supplemental oxygen Tocilizumab Trial [DOI] 10.1007/s00134-021-06507-x PMC 바로가기 [Article Type] Randomized Controlled Trial
Efficacy and safety of pegylated interferon-α2b in moderate COVID-19: a phase 3, randomized, comparator-controlled, open-label study중등도 COVID-19에서 페길화된 인터페론-α2b의 효능 및 안전성: 3상, 무작위, 비교 대조, 공개 라벨 연구Clinical Trial Published on 2021-10-012022-09-11 Journal: International Journal of Infectious Diseases [Category] SARS, 바이오마커, 임상, 치료제, [키워드] 1:1 acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 Administered adult subject adult subjects alpha-2b Arm ARMS Biomarker Biomarkers clinical status clinically conjunction coronavirus disease Coronavirus disease-19 Coronavirus-2 COVID-19 Day decrease Efficacy and safety evaluate Health Organization IFN IFN-α2b interferon interferon alpha-2b Laboratory parameters limit moderate Moderate COVID-19 Moderate subjects Open-label Ordinal Scale oxygen Pegylated interferon alpha-2b (PEG IFN-α2b) phase Phase 3 primary endpoint proportion provide Randomized receive safety profile SARS-CoV-2 seven-point ordinal scale severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 significant changes in Spread Standard of care subject subjects supplemental oxygen viable treatment viral clearance World Health Organization [DOI] 10.1016/j.ijid.2021.08.044 PMC 바로가기 [Article Type] Clinical Trial
The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study기계적 환기가 필요하지 않은 중증 COVID-19 환자에 대한 레빌리맙의 효능 및 안전성: 다기관 무작위 이중맹검 위약 대조 3상 CORONA 임상 연구 결과Clinical Trial Published on 2021-09-292022-09-12 Journal: Inflammation research : official journal of the Eu [Category] 임상, 진단, [키워드] 1:1 7-category ordinal scale administration Adverse drug reaction Adverse drug reactions all subject all subjects Clinical improvement clinical study clinical trial Combination comparable COVID-19 COVID-19 patient COVID-19 pneumonia Day Deterioration double-blind Efficacy efficacy analysis Efficacy and safety eligible evaluate Frequency groups Hospitalized IL-6 IL-6 receptor IL-6R inhibitor Infection inhibitor investigator Levilimab men Missing data multicenter non-responders objective Older Open-label Ordinal Scale oxygen Oxygen therapy Patient patients Placebo placebo-controlled primary efficacy endpoint proportion Randomized receive Registered responders Result SARS-CoV-2 pneumonia severe COVID-19 Severe COVID-19 pneumonia Standard of care subcutaneous administration subject sustained Symptoms therapy Trial Ventilation women [DOI] 10.1007/s00011-021-01507-5 PMC 바로가기 [Article Type] Clinical Trial
Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study영국 런던의 신종 SARS-CoV-2 B.1.1.7 계통의 게놈 특성 및 임상 효과: 전체 게놈 시퀀싱 및 병원 기반 코호트 연구Article Published on 2021-09-012022-09-11 Journal: The Lancet. Infectious Diseases [Category] SARS, 변종, 치료기술, [키워드] adjusted age analysed Analysis association B.1.1.7 B.1.1.7 variant Characteristics Clinical effect Clinical severity Cohort cohort study collected college Comorbidities Council Cycle threshold value death defined emergence Engineering epitope Epitopes Ethnicity Evidence evidence of genomic genomic read hospital hospitalised identify Immunocompromised patient Immunocompromised patients inclusion criteria Infection Lineage London mass vaccination monoclonal antibodies Mutation mutations NHS NIHR no evidence of Ordinal Scale Patient patients PCR PCR cycle Poisson regression model Poisson regression models positive Positive test Prevalence raise Remdesivir SARS-CoV-2 SARS-CoV-2 B.1.1.7 Science sequenced Sequencing severe disease Sex specific mutation specific mutations Spike protein Symptom the spike protein the WHO threshold value Transmissibility Trust university vaccination variant variants Viral load Virological virus load VoC WHO ordinal scale whole-genome sequencing [DOI] 10.1016/S1473-3099(21)00170-5 PMC 바로가기 [Article Type] Article
Protocol for the Controlled evaLuation of Angiotensin Receptor blockers for COVID-19 respIraTorY disease (CLARITY): a randomised controlled trialCOVID-19 호흡기 질환에 대한 안지오텐신 수용체 차단제의 통제된 평가를 위한 프로토콜(CLARITY): 무작위 통제 시험Study Protocol Published on 2021-08-282022-09-10 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 7-point ordinal scale accumulating ACE2 activities activity adaptive angiotensin Angiotensin II angiotensin receptor blocker Angiotensin receptor blockers angiotensin-converting enzyme 2 ARB ARBs AT1R Bayesian adaptive design bind blinded blocked CLARITY clinical commenced Controlled Controlled trial COVID-19 COVID-19 severity daily dose death determine disease downregulation Effect Effectiveness enzyme High-risk patients include India interim analysis membrane membrane-bound Mortality offer Open-label Ordinal Scale outcome Placebo Pragmatic Predictive primary endpoint pro-fibrotic pro-inflammatory Probability randomised controlled trial RAS RCT receptor receptor blocker Receptor Blockers recruitment reduce reducing registry Renin renin-angiotensin system respiratory respiratory outcomes responsible Safe Sample size SARS-CoV-2 secondary Secondary outcomes Standard of care supplementary material supply Treatment treatment allocation Trial Trial registration Two-arm [DOI] 10.1186/s13063-021-05521-0 PMC 바로가기 [Article Type] Study Protocol
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusionSPIKE-1: SARS-CoV-2 스파이크 단백질 개시 막 융합을 차단하여 COVID-19의 임상 진행을 줄이는 데 camostat의 사용을 평가하는 커뮤니티 환경에서의 무작위 2상/3상 시험Letter Published on 2021-08-192022-09-10 Journal: Trials [Category] MERS, SARS, 임상, [키워드] 1:1 acute respiratory syndrome coronavirus apyrexia available data baseline best Biomarkers Blinding camostat clearance Clinical improvement clinical trial Community conducted control arm coronavirus coronavirus 2 coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection COVID-19 symptom COVID-19 symptoms COVID-2019 Day defined Deterioration determined by diagnostics disease dissemination duration of illness Efficacy element eligibility criteria Eligible patients EudraCT evaluate Evidence evidence of Formal four times daily functional Guidance Health Organization health protection high risk hospital Hospital admission Hospital admissions Host include Infection initial Interactive Web Response System interim analysis Ireland IWRS Laboratory testing maximum membrane fusion moderate Mortality multicentre nasal negative swab number objective open open label Open-label Ordinal Scale outcome outcome measure overall mortality oxygen oxygen-free day Oxygenation participant Patient patient population patients with SARS-CoV-2 performed phase PK data Prevent primary care progression protection protocol provided Public Public Health Agency Public Health England qPCR questionnaire randomisation randomised randomised controlled trial receive recruit recruited recruitment reduce reducing refinement requiring supplemental oxygen Research respiratory risk RT-PCR Saliva Sample size Sample size calculations SARS-CoV-2 SARS-COV-2 infection secondary Secondary objective Secondary objectives secondary outcome measures serum antibody Severe acute respiratory syndrome severe acute respiratory syndrome coronavirus 2 severity spike status supplemental oxygen supplementary material supplementary oxygen supportive care Swab symptom severity tablets temperature the patient TMPRSS2 translational Translational research Treatment treatment arm Trial trial protocol Trial registration typical symptom typical symptoms upper respiratory Ventilation ventilator ventilator-free day Ventilator-free days Viral Viral load viral shedding website World Health Organization [DOI] 10.1186/s13063-021-05461-9 PMC 바로가기 [Article Type] Letter
A cost of illness study of COVID-19 patients and retrospective modelling of potential cost savings when administering remdesivir during the pandemic “first wave” in a German tertiary care hospitalCOVID-19 환자의 질병 비용 연구 및 독일 3차 치료 병원에서 전염병 "1차 유행" 동안 렘데시비르를 투여할 때 잠재적 비용 절감에 대한 후향적 모델링Original Paper Published on 2021-08-182022-09-10 Journal: Infection [Category] COVID19(2023년), SARS, 치료기술, [키워드] acquisition administration Analysis Care category China Clinical severity conducted coronavirus disease COVID-19 COVID-19 patient Diagnosis disease DRG eligible European Medicines Agency Germany healthcare Healthcare system Healthcare systems heterogeneous hospital Inpatient Inpatients invasive ventilation lAbel median Novel coronavirus novel coronavirus disease Ordinal Scale oxygen pandemic Patient Perspective Potential Real-life data reduced Remdesivir resource resources Result retrospective SARS-CoV-2 shown Spread supplemental oxygen treated Treatment Treatment costs university Variability variety were assessed [DOI] 10.1007/s15010-021-01685-8 PMC 바로가기 [Article Type] Original Paper
Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trialCOVID-19 중환자를 위한 Lopinavir-ritonavir 및 hydroxychloroquine: REMAP-CAP 무작위 대조 시험Randomized Controlled Trial Published on 2021-08-012022-09-11 Journal: Intensive care medicine [Category] Fulltext, SARS, 임상, 치료제, [키워드] Adaptive platform trial adjusted odds ratio antiviral therapy Bayesian combination therapy control group coronavirus disease Coronavirus disease 2019 COVID-19 credible interval Critically ill Critically ill patient critically ill patients cumulative Efficacy expressed group hospital Hydroxychloroquine in-hospital mortality intensive care Intervention Logistic Lopinavir Lopinavir-ritonavir median Ordinal Scale organ organ support outcome pandemic Patient platform Pneumonia posterior probability primary endpoint Probability Randomized Randomized controlled trial reached receive reduced REMAP-CAP Ritonavir survival threshold treatment effect treatment effects with COVID-19 worsened yielding [DOI] 10.1007/s00134-021-06448-5 PMC 바로가기 [Article Type] Randomized Controlled Trial
Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia코로나19 폐렴으로 입원한 환자의 토파시티닙Randomized Controlled Trial Published on 2021-07-292022-09-11 Journal: The New England Journal of Medicine [Category] Fulltext, MERS, 임상, 치료제, [키워드] 1:1 95% CI 95% confidence interval adverse event all-cause mortality assigned Brazil coronavirus disease Coronavirus disease 2019 COVID-19 pneumonia cumulative cumulative incidence death dose Efficacy and safety glucocorticoid Glucocorticoids hazard ratio hospital discharge Hospitalization Hospitalized incidence inhibitor Janus kinase Kinase inhibitor lower risk Mortality occurred Occurrence Ordinal Scale Patient patients hospitalized Pfizer Placebo placebo group Pneumonia Primary outcome randomization Randomly receive Respiratory failure risk risk ratio Serious Adverse Events STOP-COVID the patient the placebo group Tofacitinib [DOI] 10.1056/NEJMoa2101643 PMC 바로가기 [Article Type] Randomized Controlled Trial
Impact of AYUSH interventions on COVID-19: a protocol for a living systematic review and meta-analysisCovid-19에 대한 Ayush 개입의 영향 : 살아있는 체계적인 검토 및 메타 분석을위한 프로토콜Study Protocol Published on 2021-07-282022-08-31 Journal: F1000Research [Category] COVID-19, MERS, meta-analysis, SARS, [키워드] Admission adverse events article articles assessment Ayurveda Ayurvedic medicine AYUSH carried CENTRAL certainty clinical Clinical improvement clinical study Complementary therapies Controlled trial controlled trials coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 infection CTRI database determine development Digital duration of hospitalization Effectiveness Evidence facilitate Government GRADE Health Organization health-care high dependency unit Impact incidence India Intervention management mechanical ventilator Medicine Meta-analysis Mortality Naturopathy Ordinal Scale outcome pandemic portal Primary outcomes professionals protocol registry Research resolved risk of bia secondary Secondary outcomes severity of COVID-19 Siddha symptom resolution System systematic review systematic review and meta-analysis therapy Traditional Viral viral clearance WHO WHO ordinal scale World Health Organization yoga [DOI] 10.12688/f1000research.55109.1 PMC 바로가기 [Article Type] Study Protocol